Clinical trials: Anlotinib
Locally Advanced Thyroid Gland Carcinoma
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
The current study aims to explore the potential advantages of anti-cancer therapy that is implemented based on drug sensitivity testing.
- Trial name
- NCT06482086
- Testing
- Anlotinib, Lenvatinib, Sorafenib
- Where
- China
- Volunteers
- 75 people
- Sponsor
- West China Hospital
Nasopharyngeal Carcinoma
Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal Carcinoma
This is a Phase III randomized controlled multi-center trial comparing anlotinib plus Gemcitabine/Cisplatin with placebo plus Gemcitabine/Cisplatin in previous untreated patients with recurrent/metastatic Nasopharyngeal…
- Trial name
- NCT03601975
- Testing
- Gemcitabine/Cisplatin
- Where
- China
- Volunteers
- 336 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Carcinoma, Non-Small-Cell Lung
Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients
The purpose of this study is to determine whether concurrent chemoradiotherapy combination with Anlotinib is safe, effective in the treatment of unresectable stage III NSCLC patients.
- Trial name
- NCT03672136
- Testing
- Anlotinib, Concurrent Chemoradiotherapy
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Shandong Cancer Hospital and Institute
Diffuse Large B-cell Lymphoma
A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma
This is an open-label, single-center, single-arm study to evaluate the efficacy and safety of Anlotinib Hydrochloride Capsules in subjects with diffuse large B-cell lymphoma.
- Trial name
- NCT04827004
- Testing
- Anlotinib Hydrochloride Capsules
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression
To evaluate the efficacy and safety of anlotinib combined with TQB2450 and the SOX regimen as first-line treatment for advanced gastric cancer with low PD-L1 expression
- Trial name
- NCT06939452
- Testing
- anlotinib +TQB2450 + Oxaliplatin+S-1
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Yongxu Jia
Head and Neck Squamous Cell Carcinoma
Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1
This trial is main evaluate the efficacy and safety of Pembrolizumab combined with Anlotinib in the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma with CPS≥1
- Trial name
- NCT04999800
- Testing
- Pembrolizumab, Anlotinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shi Yuankai
Advanced Squamous Non-Small Cell Lung Carcinoma
TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.
This is Phase 3, randomized, double-blind, parallel controlled study designed to evaluate the Progression Free Survive (PFS) of TQB2450 injection combined with Paclitaxel Injection and Carboplatin Injection Followed by TQB2450…
- Trial name
- NCT05718167
- Testing
- TQB2450, Anlotinib hydrochloride capsule, Tislelizumab injection
- Where
- 4 sites in China
- Volunteers
- 570 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
SCLC, Extensive Stage
A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer
This is a single-center, single-arm, exploratory clinical study conducted at Shanghai Pulmonary Hospital, Tongji University. It aims to evaluate the efficacy and safety of first-line treatment with benmelstobart plus anlotinib…
- Trial name
- Aurora 005 (NCT07538271)
- Testing
- benmelstobart, Anlotinib, Carboplatin or cisplatin
- Volunteers
- 33 people
- Sponsor
- Yayi He
Non-squamous Non-small Cell Lung Cancer
Phase I Study of the Combination of Anlotinib With Gefitinib
The purpose of this clinical study is to evaluate the tolerability and toxicity of different dose of Anlotinib puls Gefitinib in First-line Treatment of Advanced Gene Positive Non-squamous Non-small Cell Lung Cancer , to provide…
- Trial name
- NCT03602027
- Testing
- Anlotinib, Gefitinib
- Volunteers
- 9 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Gynecological Cancer
A Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological Cancer
This is a single-arm, open-label, phase Ib clinical trial to evaluate the efficacy and safety of TQB2450 combined with anlotinib in subjects with gynecological cancer, including 34 ovarian cancer，34 endometrial cancer，22 cervical…
- Trial name
- NCT04236362
- Testing
- TQB2450, Anlotinib
- Where
- 5 sites in China
- Volunteers
- 90 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Nasopharyngeal Carcinoma
GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.
The investigators have designed a multicenter, open-label, randomized controlled phase III clinical study of GAPP induction therapy followed by concurrent chemoradiotherapy and toripalimab maintenance therapy for high-risk…
- Trial name
- NCT07540390
- Testing
- Toripalimab, Anlotinib, Cisplatin
- Where
- China
- Volunteers
- 442 people
- Sponsor
- Sun Yat-sen University
Bile Duct Carcinoma, Gall Bladder Cancer
Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer
Brief Summary: This study is for patients with advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The purpose is to find out if using anti-blood vessel formation drugs after immunotherapy treatment can help…
- Conditions
- Bile Duct Carcinoma, Gall Bladder Cancer, Biliary Tract Cancer, Cholangiocarcinoma
- Trial name
- SAIB (NCT07025174)
- Testing
- PD-1/CTLA-4 Dual Functional Antibody, Gemcitabine, Cisplatin, Anlotinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Lung Cancer, TKI Resistance
A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody
Lung cancer is the second most common malignancy and mortality rate in the world. In the United States and Europe, approximately 10% to 15% of NSCLC patients have epidermal growth factor receptor (EGFR)-sensitive mutations, with…
- Conditions
- Lung Cancer, TKI Resistance, EGFR Sensitive Mutation, Anlotinib
- Trial name
- NCT06048315
- Testing
- Anlotinib, Penpulimab
- Volunteers
- 52 people
- Sponsor
- Degan Lu
Locally Advanced or Metastatic Acral Malignant Melanoma
Toripalimab Combined With Anlotinib in Unresectable Locally Advanced or Metastatic Acral Malignant Melanoma
Evaluate PFS of PD-1 Toripalimab Combined With Anlotinib in Subjects With unresectable locally advanced or metastatic acral malignant melanoma
- Trial name
- NCT05087602
- Testing
- Toripalimab and Anlotinib
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Qilu Hospital of Shandong University
Whole Brain Radiotherapy
Antirotinib Hydrochloride Plus Whole Brain Radiotherapy for Small Cell Lung Cancer With Brain Metastases
The objective of this study was to evaluate the efficacy and safety of whole brain radiotherapy combined with antirotinib hydrochloride in the treatment of brain metastases in small cell lung cancer
- Trial name
- NCT06611657
- Testing
- Antirotinib hydrochloride
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Renal Cell Carcinoma
Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs Therapy
Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.
- Trial name
- NCT02072044
- Testing
- Anlotinib
- Where
- 15 sites in China
- Volunteers
- 60 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Effect of Drugs, Quality of Life
Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma
For local relapse not amenable to reasonable curative surgery or for those with metastatic chordoma, chemotherapy is recognised as inactive.
- Conditions
- Effect of Drugs, Quality of Life, Chordoma, Advanced Cancer
- Trial name
- CSSG-03 (NCT04042597)
- Testing
- Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University People's Hospital
HCC
Novel Treatment of Advanced Hepatocellular Carcinoma
The purpose of this study is to evaluate the efficacy and safety of arginine hydrochloride combined with Levamisole in the treatment of patients with hepatocellular carcinoma.
- Trial name
- NTAHCC (NCT03950518)
- Testing
- Anlotinib Hydrochloride Capsules, Arginine hydrochloride, levamisole
- Where
- China
- Volunteers
- 300 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Extensive Stage Small Cell Lung Cancer
Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer
This is a randomized, controlled, open-label, multicenter clinical study to evaluate the efficacy and safety of carboplatin/cisplatin + etoposide + benmelstobart sequential benmelstobart combined with anlotinib versus…
- Trial name
- NCT06897579
- Testing
- Carboplatin for injection/cisplatin for injection + etoposide injection + benmelstobart injection + Anlotinib hydrochloride capsule, Carboplatin for injection/Cisplatin for injection + etoposide injection + Tislelizumab injection
- Where
- 32 sites in China
- Volunteers
- 40 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non-Small Cell Lung Cancer
Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC
This is a phase II, open-label, single-arm, single-center clinical study to evaluate the preliminary efficacy of sunvozertinib in combination with anlotinib in patients with EGFR-sensitive mutations and co-mutations in locally…
- Trial name
- WUKONG-32 (NCT06348927)
- Testing
- sunvozertinib in combination with Anlotinib
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Hunan Province Tumor Hospital